What we have done to date.

1. What we have done to date. The first most critical choice when creating a new PDT technology is the sensitizer. For our base molecule we chose Aluminium hydroxyl Phthalocyanine di-sulfonate This molecule is recognized as nearly perfect but has been abandoned due to extremely high cost of purification. We had to evolve new synthesis techniques, but now we can produce it at a very low cost and high quality. On it’s own this sensitizer is 10 times more powerful than the one in common use, and it is about 3 times more specific in it’s preference for cancer over normal tissue.

2. Going for the Gold We could have stopped there, but we chose to continue to perfect the sensitizer by the addition of several adjuvants. This molecule causes the cancer to attract our nano-molecule with electrostatic fields, like a star wars tractor beam, and it carries the sensitizer directly into the cancer. This molecule suppresses BCL-2, which leaves the cancer cell depressed and suicidal. In medical terms, it modulates the anti-apoptotic enzyme downwardly. This molecule gives a “down shields” command to cancer by interrupting glutathione synthesis

3. PDT technology allows us to do PDD in real time to see where the sensitizer, and therefore cancer, is located. We can also measure the amount of sensitizer available for killing cancer cells. 15 min after IV injection Lymph node involvement

4. With all this technology in place, what do you do with it? Well, first you do a few animal tests, which we completed early this year. Then you need trial subjects, so we started with two patients treated under SAS protocol. In the first patient treatment was stopped at a 75% kill to see how the immune system responded. Six months later the tumour was 12 ml but encapsulated by approximately 40 ml of inflammation caused by the immune system attacking and containing the cancer. On the 29th November we started the process of eliminating all of the cancer. Ultrasound evaluation was followed by a single treatment cycle. This eliminated 3ml of tumour within 4 days. The second treatment was started on the 6th of December and evaluation was done on the 14th of December. The reports and images from before, during and after this short treatment cycle follow.

8. Analysing the results. • When the decision was made to eliminate the tumour, the entire process from beginning to end including delays to document progress took a little over two weeks, and two sequences of treatments. Extra time was spent in an experimental treatment inside this time frame to determine the effect of anti-oxidants. • In short, we have demonstrated the following. • This technology can create and maintain a sustained immune response within the patient which is capable of controlling cancer. • Cancer can be killed within the intact breast with minimal damage to normal tissue. • With this technology it is possible to kill and liquify a stage T3 tumour with only two treatment cycles.

9. What more could you ask for? • PDT is surprisingly inexpensive to set up and administer. • It can be an outpatient procedure, so instead of taking up bed space and precious staff resources, it can reduce patient load. • The equipment for PDT is incredibly inexpensive considering how effective it is in treating a variety of diseases. • There are several molecules which can be modified to produce our own sensitizer which would is better than any sensitizer being marketed today. • We have the expertise to actually be in the front of the pack in this exciting medical technology right here in Australia. • It is possible to take the lead in bringing this therapy to all of Australia. It is within our reach, if we but try.

10. For more information go to http://www.cytoluminator.com Or email cytoluminator@gmail.com Or call 0407 337 133 and ask for Terry. This information was compiled and presented by Terry Wright